ScreenerHero

NGNE Neurogene Inc.

NAS · US · Healthcare · Biotechnology · neurogene.com
25.87USD+1.65%Mkt Cap: 517.69M $P/E: —

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which i…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap517.69M USD
Enterprise Value292.24M USD
Revenue (TTM)—
Gross Profit-88.38M USD
Net Income (TTM)-90.35M USD
Revenue/Share—
Last Price25.87 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees131
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.92
PEG—
EV/EBITDA-2.48
EV/Revenue—
P/S—
P/B1.86
EPS (TTM)-5.04
EPS (Forward)-5.18
52W Range
15.9336% of range43.66
52W High43.66 USD
52W Low15.93 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-34.11%
ROA-31.31%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-77.17M USD
CapEx (TTM)1.18M USD
FCF Margin—
FCF Yield-9.29%
Net Debt-217.05M USD
Net Debt/EBITDA1.84
Balance Sheet
Debt/Equity0.04
Current Ratio10.64
Quick Ratio10.50
Book Value/Sh13.72 USD
Cash/Share11.26 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:4
Split DateDec 19, 2023
Analyst Consensus
Rating—
Target (Mean)80.43 USD
Upside (mean)+210.9%
Target Range46.00 USD – 166.00 USD
46.00+210.9% to mean166.00
# Analysts7
Ownership
Shares Out.20.01M
Float11.30M
Insiders6.98%
Institutions88.98%
Short Interest
Short Ratio15.2d
Short % Float19.45%
Short % Out.16.39%
Shares Short3.28M
Short (prev mo.)3.04M
Technical
SMA 5034.59 (-25.2%)
SMA 20027.26 (-5.1%)
Beta2.09
S&P 52W Chg15.78%
Avg Vol (30d)298.96K
Avg Vol (10d)338.34K
Technical Indicators
RSI (14)29.4
MACD-2.7450
MACD Signal-2.2069
MACD Hist.-0.5382
BB Upper39.41 USD
BB Middle31.00 USD
BB Lower22.58 USD
BB Width54.30%
ATR (14)1.955 USD
Vol Ratio (20d)0.34x